Interventional Glaucoma

Robert L Stamper, MD, raises the question of physician liability for allowing the patient to drive.

Shan C. Lin, MD, discusses combined minimally invasive glaucoma surgery and its impact on achieving improved intraocular pressure efficacy.

Joseph Panarelli, MD, sat down with David Hutton of Ophthalmology Times to discuss the panel he moderated at the Glaucoma 360 meeting held in San Francisco, about innovations in glaucoma drugs, and drug delivery.

Adrienne Graves, PhD, and Andrew Iwach, MD, co-founders of Glaucoma 360, highlight the 13th annual Glaucoma 360 New Horizons Forum, held this year at the Westin St. Francis San Francisco on Union Square.

According to the company, the patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields

Standalone, minimally-invasive glaucoma treatments

According to the company, the research is being conducted in collaboration with London-based Imperial College Healthcare NHS Trust.

The partnership establishes a large-scale enrollment platform for research on MicroPulseTransscleral Laser Therapy (TLT)

The new contact lenses contain micro-sensors which monitor changes in IOP over a period of several hours, sending the data collected wirelessly so it can be analyzed by an ophthalmologist and a diagnosis given.

Researchers are unveiling results show previously unknown inherited genetic variants that contribute to primary open-angle glaucoma, the most common form of the disease.

TRS01 ophthalmic solution is targeted for the treatment of non-infectious uveitis, including uveitic glaucoma.

Researchers at Indiana University School of Medicine will focus on providing a foundation for developing a new glaucoma therapeutic by testing human neurons and a regenerative therapy to rescue visual neurons from dying preclinically in human eyes under glaucoma conditions.

Prevent Blindness will offer downloadable fact sheets, shareable social media graphics and educational videos for patients

All five MACs have now issued statements that the final LCDs will not go into effect on January 29, 2024. The MACs had identified certain procedures as investigational for glaucoma management in patients over the age of 18.

Available information includes a new promotional toolkit for The Glaucoma Community, glaucoma patient testimonial, and medical expert interview videos.

David Hutton of Ophthalmology Times talks with Jay Katz, MD, CMO for Glaukos, and Steven R. Sarkisian, MD, about the Glaukos iDose travoprost implant.

In 2024, the waiting game will pay off for glaucoma specialists who are eager to develop fluency and implement new devices into their practices

Analysis suggested no evidence for a causal association of lifetime cannabis use and cannabis use disorder with primary open-angle glaucoma

Glaukos Corp's iDose TR has received FDA approval for the reduction of IOP in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG) following a new drug application (NDA) submission.

A Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser, the Eagle is intended for use in performing selective laser trabeculoplasty.

The system hopes to use optical coherence tomography (OCT), while at the same time, leverage air and ultrasonic pulses to excite the mechanical waves in the cornea, enabling the detection of normotensive glaucoma.

MACs categorize goniotomy, canaloplasty, cyclophotocoagulation as experimental; glaucoma specialists speak out.

Analisa Arosemena, MD, underscores the importance of year-round glaucoma control through extended-release medications and laser treatments at EyeCon 2023.

Oluwatosin U. Smith, MD, and Peter J. McDonnell, MD, discuss their experience at EyeCon 2023, highlighting the latest updates in retina, cataract and refractive surgery, and the growing epidemic of myopia worldwide.

The Phase 2 study is evaluating the efficacy and safety using 2 concentrations of SBI-100 OE vs. placebo, dosing twice a day for 14 days.